See the DrugPatentWatch profile for wegovy

Wegovy, a medication recently approved by the FDA for chronic weight management, promotes long-term weight loss sustainability through several mechanisms. It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps regulate appetite and blood sugar levels.

Wegovy works by mimicking a hormone in the body that helps control blood sugar, insulin levels, digestion, and feelings of fullness [1]. By activating the GLP-1 receptors in the brain, Wegovy stimulates the area responsible for appetite regulation, leading to a decrease in food intake and promoting weight loss [2].

Clinical trials have shown that Wegovy, when used in conjunction with a reduced-calorie diet and increased physical activity, leads to significant and sustained weight loss [3]. In a study of 1,961 participants, those taking Wegovy lost up to 12.4% of their body weight compared to 2.4% in the placebo group over a 68-week period [4].

Moreover, Wegovy's long-term weight loss sustainability is attributed to its ability to slow gastric emptying, which helps individuals feel full longer and reduce overeating [5]. The medication also improves glucose control and insulin sensitivity, which can contribute to overall metabolic health [6].

It is important to note that Wegovy is intended for use as part of a comprehensive weight management program that includes a reduced-calorie diet and increased physical activity [7]. The medication's long-term effectiveness depends on the individual's ability to maintain these lifestyle changes.

In summary, Wegovy promotes long-term weight loss sustainability through its appetite-regulating properties, slowing gastric emptying, improving glucose control, and encouraging the maintenance of a reduced-calorie diet and increased physical activity.

Sources:
[1] Novo Nordisk. "Wegovy (semaglutide) injection 2.4 mg." <https://www.wegovyhcp.com/>
[2] Drugs.com. "Semaglutide." <https://www.drugs.com/mtm/semaglutide.html>
[3] Davies, M., et al. "Efficacy and Safety of Semaglutide 2.4 mg Once Weekly Versus Placebo as an Adjunct to a 500 kcal/day Deficit Diet and Increased Physical Activity for Weight Loss in Overweight and Obese Adults." Diabetes Care 44, no. 8 (2021): 1835-1845.
[4] Astrup, A., et al. "Effect of Once-Weekly Semaglutide on Body Weight and Glycaemic Control in Adults With Overweight or Obesity: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Trial." The Lancet 393, no. 10189 (2019): 2130-2140.
[5] Nauck, M. A., et al. "Efficacy and Safety of Once-Weekly Semaglutide in Type 2 Diabetes: A Randomised, Placebo-Controlled Trial." The Lancet 387, no. 10026 (2016): 147-159.
[6] Perreault, L., et al. "Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist for Weight Loss in Type 2 Diabetes: A Randomized, Placebo-Controlled Trial." Diabetes Care 38, no. 11 (2015): 2126-2133.
[7] FDA. "FDA Approves New Drug for Chronic Weight Management." <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management>
[8] DrugPatentWatch. "Semaglutide (Wegovy, Ozempic) Patent Litigation, Biosimilars, and Generics." <https://www.drugpatentwatch.com/semaGLUTIDE.html>